Global Achondroplasia Treatment Market Growth (Status and Outlook) 2023-2029

Global Achondroplasia Treatment Market Growth (Status and Outlook) 2023-2029

Achondroplasia is a disorder of bone growth that prevents the changing of cartilage (particularly in the long bones of the arms and legs) to bone. It is characterized by dwarfism, limited range of motion at the elbows, large head size (macrocephaly), small fingers, and normal intelligence. Achondroplasia (ACH) is a rare disease that causes short stature (adult height of approximately 130 cm for males and approximately 125 cm for females) with short limbs. There is no effective treatment available, and this disease is designated as an intractable disease by the Ministry of Health, Labour and Welfare. This disease results mainly from a genetic defect in FGFR3 (fibroblast growth factor type 3 receptor). This genetic change causes the receptor to be overly active to growth factors such as FGF2, which leads to reduced growth of chondrocytes, resulting a short stature. ACH occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
LPI (LP Information)' newest research report, the “Achondroplasia Treatment Industry Forecast” looks at past sales and reviews total world Achondroplasia Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Achondroplasia Treatment sales for 2023 through 2029. With Achondroplasia Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Achondroplasia Treatment industry.
This Insight Report provides a comprehensive analysis of the global Achondroplasia Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Achondroplasia Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Achondroplasia Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Achondroplasia Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Achondroplasia Treatment.
The global Achondroplasia Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The main global Achondroplasia Treatment players include Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas, etc. North America is the largest consumer market for Achondroplasia Treatment, accounting for about 46%, followed by Europe and China. In terms of type, CNP Analogue is the largest segment, with a share over 57%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report presents a comprehensive overview, market shares, and growth opportunities of Achondroplasia Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
CNP Analogue
Ligand Trap
TKI
Others
Segmentation by application
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ascendis Pharma
BioMarin
Ribomic
QED Therapeutics
Pfizer
Astellas

Please note: The report will take approximately 2 business days to prepare and deliver.